Also, in breast cancer patients with unclear HER2 (positive/negative) status after normal evaluation with [18F]-FDG PET-scan, [89Zr]Zr-DFO-trastuzumab immuno-PET could assist physicians in treatment planning [110]. This evidence concerns the gene ERBB2 and breast carcinoma.